Search Results

You are looking at 31 - 40 of 524 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Association Between Frailty and Time Alive and At Home After Cancer Surgery Among Older Adults: A Population-Based Analysis

Julie Hallet, Bourke Tillman, Jesse Zuckerman, Matthew P. Guttman, Tyler Chesney, Alyson L. Mahar, Wing C. Chan, Natalie Coburn, Barbara Haas, and members of the Recovery after Surgical Therapy for Older adults Research–Cancer (RESTORE-Cancer) Group

). Adjusted for age (categorical), sex, rural residence, comorbidity burden, material deprivation, immigration status, stage at diagnosis, year of surgery, neoadjuvant therapy, adjuvant therapy, intensity of surgical procedure, and cancer type. Subgroup

Full access

Decision-Making For Patients With Resectable Breast Cancer: Individualized Decisions For and By Patients and Their Physicians

Charles L. Loprinzi and Peter M. Ravdin

. 5 Ravdin PM Siminoff LA Davis GJ . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer . J Clin Oncol 2001 ; 19 : 980 - 991 . 6 Loprinzi CL Thome SD . Understanding the utility

Full access

Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma

Anthony J. Olszanski

Patients with stage III melanoma are at high risk for disease recurrence, but adjuvant therapy—including targeted therapy and immunotherapy—may prevent or delay relapse, according to Anthony J. Olszanski, MD, RPh, Associate Professor and Vice Chair

Full access

Multidisciplinary Management of Early-Stage Rectal Cancer

John G. Phillips, Theodore S. Hong, and David P. Ryan

management of patients with rectal cancer. Discuss the role of adjuvant therapy in the management of rectal cancer. Patients with AJCC stage II (invasion through the muscularis layers) and III (node-positive) rectal cancer are at high risk for both

Full access

CLO21-021: Impact on Survival of the Number of Lymph Nodes Resected in Patients With Esophageal Cancer Following Neo-Adjuvant Therapy

Jordan McDonald, Anupam Rishi, Sabrina Saeed, Rutika Mehta, David Pointer, Jessica Frakes, Sarah Hoffe, Jacques Fontaine, and Jose Pimiento

Full access

NCCN Guidelines Updates: Pancreatic Cancer

Margaret A. Tempero

Panel Adds to Pancreatic Cancer Recommendations For the first time in decades, advances in diagnostics and adjuvant therapies appear to be improving outcomes in pancreatic cancer. These advances are reflected in additions to the NCCN Clinical

Full access

Updates in Clinical Management of Pancreatic Cancer

Presented by: Andrew H. Ko

, he added (ClinicalTrials.gov identifier: NCT01013649 ). Additionally, even for up-front resectable tumors, neoadjuvant therapy has gained traction because of its conceptual advantages over adjuvant therapy ( Figure 3 ). The results of both the

Full access

VATS Versus Open Surgery for Lung Cancer Resection: Moving Toward a Minimally Invasive Approach

Jacob Klapper and Thomas A. D’Amico

. The thoracoscopic approach is oncologically equivalent to thoracotomy, while resulting in fewer complications, improved quality of life, shorter length of stay, and superior compliance with adjuvant therapies. 6 – 8 Oncologic Outcomes The

Full access

Principles of Management of Patients With Ampullary Adenocarcinoma

Presented by: Stephen W. Behrman

, patients are categorized based on the predominant subtype. Although the prognostic value of subtyping relative to adjuvant therapy and neoadjuvant therapy remains unclear, Dr. Behrman underscored the importance of subtyping for future therapeutic

Full access

Counterpoint: The Case Against Adjuvant High-Dose Interferon-α for Melanoma Patients

Paul B. Chapman

analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system . J Clin Oncol 2001 ; 19 : 3622 – 3634 . 2 Kirkwood JM Strawderman MH Ernstoff MS . Interferon alfa-2b adjuvant therapy of high